Help and Resources

Here, you'll find lots of resources to help you whether you're a patient, carer, fundraiser or medical professional.

Private: Know your rights toolkit

We have produced a number of bitesize pieces of information to help you understand the options that are available to you, access further information and make informed decisions.

Information booklets

All our information is PIF tick accredited and free to download, see a full range of downloadable informaton below. To order any hardcopy information head to our shop.

Leukaemia Matters magazine

Leukaemia Matters magazine: where you'll feel informed, empowered, and supported.

Fundraising Resources

Get your fundraising off to a flying start with our selection of downloadable materials.

Our reports

Our reports are based on the findings from our surveys and are written with the patient in mind.

Our strategic plan

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. Over the last 50 years, we have come a long way, but there is more to be done.

Read More

Take a Moment to Catch Up

View our latest news and blog articles

October 10th

How our fundraisers have supported Leukaemia Care during Blood Cancer Awareness Month!

September marked Blood Cancer Awareness Month, and throughout the month, a wide range of people raised money for Leukaemia Care, helping to raise awareness and support of our work. ...

October 4th

New treatment for patients with mastocytosis in England and Wales

Leukaemia Care and UK Masto are pleased to announce that Avapritinib (Ayvakyt©) has been approved for treating advanced systemic mastocytosis in adults in England and Wales, thanks to a decision made by the National Institute for Health and Care Excellence (NICE)....

September 19th

Additional treatment for AML patients now available in England

Leukaemia Care is pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patients with a FLT3 mutation now have access to quizartinib, in combination with chemotherapy, thanks to a decision made by the National Institute for Health and Care Excellence (NICE) today....